ASX:CSLBiotechs
Assessing CSL (ASX:CSL) Valuation As Half Year Results And Seqirus Uncertainty Approach
Investors are eyeing CSL (ASX:CSL) ahead of its February 11 half year results, with last year's profit guidance downgrade, the delayed Seqirus spin off and weaker US flu vaccinations still shaping sentiment.
See our latest analysis for CSL.
CSL shares recently saw a 1-day share price return of a 1.15% decline to A$180.19. However, the 7-day and 30-day share price returns of 2.32% and 3.83% suggest some near term momentum after a weak year, with a 1-year total shareholder return of a 33.75%...